source
- Neurosterix raises $105 million Series B to advance schizophrenia candidateNeurosterix announced it has closed a $105 million Series B financing round. The capital will be used to develop its lead drug candidate for schizophrenia, which targets a pathway also addressed by…
- Merck KGaA receives FDA approval for Abbisko-licensed joint tumor therapyMerck KGaA announced that the U.S. Food and Drug Administration has granted approval to a drug it licensed from Chinese biotech Abbisko. The approval covers treatment of rare non-cancerous tumors t…